This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
et al | 10938 |
acute respiratory | 1592 |
respiratory syndrome | 1556 |
risk factors | 1423 |
novel coronavirus | 1367 |
intensive care | 1324 |
public health | 1088 |
stem cell | 1025 |
immune response | 1014 |
severe acute | 994 |
immune system | 976 |
author funder | 967 |
granted medrxiv | 966 |
virus infection | 950 |
infectious diseases | 924 |
influenza virus | 886 |
copyright holder | 885 |
syndrome coronavirus | 883 |
coronavirus disease | 793 |
systematic review | 788 |
middle east | 758 |
care unit | 757 |
united states | 756 |
critically ill | 742 |
gene expression | 732 |
increased risk | 731 |
bone marrow | 728 |
mg kg | 727 |
respiratory tract | 722 |
health care | 703 |
east respiratory | 683 |
immune responses | 677 |
mechanical ventilation | 676 |
epithelial cells | 669 |
cell transplantation | 666 |
significantly higher | 643 |
pregnant women | 624 |
clinical characteristics | 608 |
respiratory distress | 604 |
clinical trials | 595 |
median age | 589 |
cancer patients | 588 |
septic shock | 587 |
statistically significant | 583 |
case report | 583 |
ill patients | 579 |
made available | 573 |
present document | 571 |
peripheral blood | 565 |
cord uid | 553 |
doc id | 553 |
international license | 552 |
viral infections | 540 |
control group | 533 |
version posted | 529 |
ace expression | 526 |
mean age | 526 |
innate immune | 524 |
risk factor | 523 |
type diabetes | 520 |
years old | 519 |
infectious disease | 508 |
viral infection | 507 |
converting enzyme | 498 |
world health | 492 |
cohort study | 478 |
may also | 476 |
summary conclusions | 468 |
lung injury | 466 |
significant difference | 466 |
zika virus | 461 |
distress syndrome | 459 |
diabetes mellitus | 457 |
hematopoietic stem | 457 |
food safety | 454 |
health organization | 449 |
two groups | 446 |
blood donors | 445 |
high risk | 444 |
one patient | 442 |
clinical trial | 439 |
breast cancer | 438 |
adverse events | 437 |
among patients | 437 |
medrxiv preprint | 433 |
ng ml | 432 |
antiviral activity | 430 |
clinical features | 428 |
patients received | 427 |
critical care | 424 |
heart failure | 419 |
saudi arabia | 417 |
immune cells | 415 |
patients admitted | 407 |
severe covid | 401 |
blood pressure | 395 |
mortality rate | 392 |
amino acid | 390 |
safety authority | 388 |
european food | 388 |
inflammatory cytokines | 387 |
spinal cord | 386 |
stem cells | 385 |
prostate cancer | 385 |
peer review | 375 |
pulmonary disease | 372 |
oxidative stress | 370 |
animal models | 369 |
icu admission | 369 |
respiratory failure | 369 |
nk cells | 365 |
immunodeficiency virus | 363 |
logistic regression | 363 |
side effects | 360 |
viral load | 357 |
hiv infection | 353 |
retrospective study | 353 |
overall survival | 351 |
cardiovascular disease | 350 |
whole blood | 347 |
dengue virus | 346 |
mg dl | 345 |
performed using | 342 |
mouse model | 341 |
nervous system | 340 |
blood group | 340 |
human immunodeficiency | 339 |
significant differences | 338 |
chronic obstructive | 338 |
viral replication | 337 |
flow cytometry | 337 |
hand hygiene | 334 |
disease control | 334 |
patients treated | 333 |
infected patients | 333 |
lung disease | 333 |
patients receiving | 332 |
higher risk | 329 |
coronavirus infection | 324 |
cd cells | 323 |
tract infections | 322 |
obstructive pulmonary | 321 |
lung cancer | 320 |
influenza viruses | 318 |
inflammatory response | 317 |
respiratory syncytial | 315 |
severe disease | 314 |
hospitalized patients | 313 |
avian influenza | 313 |
cd cd | 313 |
dendritic cells | 311 |
clinical outcomes | 310 |
respiratory infections | 309 |
cell types | 309 |
viral rna | 307 |
least one | 306 |
previous studies | 306 |
blood transfusion | 306 |
lung function | 305 |
ebola virus | 304 |
present study | 301 |
syncytial virus | 300 |
disease severity | 297 |
observational study | 297 |
general population | 296 |
patients undergoing | 296 |
endothelial cells | 295 |
controlled trial | 293 |
patients infected | 292 |
rights reserved | 291 |
cell surface | 290 |
allowed without | 290 |
without permission | 290 |
reuse allowed | 290 |
randomized controlled | 287 |
important role | 287 |
hospital mortality | 287 |
growth factor | 287 |
cell lines | 285 |
air pollution | 285 |
global health | 284 |
two patients | 284 |
confirmed cases | 283 |
organ failure | 281 |
insulin resistance | 280 |
adult patients | 278 |
posted may | 278 |
drug resistance | 277 |
case series | 274 |
patients without | 269 |
factors associated | 269 |
transplant recipients | 268 |
blood cells | 267 |
clinical practice | 267 |
reactive protein | 267 |
red blood | 266 |
nucleic acid | 265 |
cell death | 264 |
older adults | 264 |
urinary tract | 264 |
infected cells | 263 |
pediatric patients | 263 |
cardiac arrest | 260 |
significantly lower | 260 |
prospective study | 260 |
lower respiratory | 260 |
heart disease | 255 |
multivariate analysis | 255 |
sars coronavirus | 255 |
acute lung | 255 |
median time | 254 |
respiratory viruses | 253 |
high levels | 252 |
central nervous | 250 |
herpes simplex | 249 |
spike protein | 246 |
upper respiratory | 243 |
host disease | 243 |
host cell | 243 |
significantly associated | 241 |
cov infection | 240 |
monoclonal antibody | 239 |
physical activity | 239 |
ethics regulations | 238 |
clinical course | 238 |
informed consent | 236 |
severe cases | 236 |
cytokine storm | 234 |
innate immunity | 234 |
age groups | 234 |
virus replication | 233 |
life cycle | 233 |
infection control | 233 |
university hospital | 233 |
hospital stay | 232 |
data collection | 229 |
systemic inflammation | 227 |
viral entry | 227 |
necrosis factor | 227 |
age group | 226 |
adverse effects | 226 |
family members | 225 |
hubei province | 224 |
natural killer | 222 |
host cells | 220 |
study period | 220 |
virus type | 220 |
staphylococcus aureus | 219 |
escherichia coli | 216 |
pulmonary fibrosis | 215 |
pg ml | 213 |
respiratory disease | 213 |
odds ratio | 213 |
adaptive immune | 212 |
clinical manifestations | 212 |
simplex virus | 211 |
sample size | 210 |
median follow | 209 |
immune function | 208 |
ethics committee | 208 |
nk cell | 207 |
influenza infection | 207 |
may lead | 206 |
antibiotic resistance | 206 |
monoclonal antibodies | 205 |
virus infections | 205 |
influenza vaccine | 204 |
free survival | 204 |
first time | 203 |
coronavirus pneumonia | 203 |
angiotensin ii | 203 |
de novo | 202 |
zikv infection | 202 |
determine whether | 202 |
seasonal influenza | 201 |
weight loss | 201 |
cell proliferation | 201 |
replacement therapy | 201 |
fatty acids | 200 |
mental health | 200 |
conditioning regimen | 199 |
posted april | 199 |
disease progression | 198 |
clinical symptoms | 198 |
patients underwent | 198 |
blood donation | 197 |
retrospective cohort | 197 |
tumor necrosis | 196 |
west nile | 196 |
body weight | 195 |
issues addressed | 195 |
acute gvhd | 195 |
mg ml | 195 |
study showed | 194 |
conclusions reached | 194 |
fatality rate | 194 |
authority reserves | 194 |
like receptor | 194 |
awarded following | 193 |
tender procedure | 193 |
transparency principle | 193 |
published complying | 193 |
output adopted | 193 |
blood cell | 192 |
chronic gvhd | 192 |
medical records | 192 |
retrospective analysis | 192 |
adipose tissue | 192 |
clinical presentation | 191 |
significantly increased | 191 |
renal function | 191 |
mouse models | 191 |
yellow fever | 191 |
emergency department | 190 |
amino acids | 190 |
autoimmune diseases | 190 |
renal failure | 190 |
care units | 190 |
healthcare workers | 189 |
incubation period | 189 |
included patients | 188 |
blood samples | 188 |
healthy controls | 188 |
multiple myeloma | 188 |
clinical data | 188 |
influenza vaccination | 188 |
authors declare | 187 |
statistical analysis | 187 |
within days | 187 |
regression analysis | 187 |
cell line | 186 |
inclusion criteria | 186 |
transcription factor | 186 |
chain reaction | 186 |
icu patients | 186 |
without prejudice | 185 |
cystic fibrosis | 185 |
respiratory symptoms | 185 |
bodies identified | 184 |
developing countries | 183 |
palliative care | 183 |
wide range | 183 |
brain injury | 183 |
young children | 183 |
magnetic resonance | 183 |
recent study | 183 |
bacterial infections | 183 |
polymerase chain | 182 |
rheumatoid arthritis | 182 |
allogeneic hematopoietic | 182 |
tract infection | 181 |
rna viruses | 181 |
total number | 180 |
long term | 180 |
mortality rates | 180 |
bacterial infection | 180 |
kidney injury | 179 |
commonly used | 179 |
one year | 178 |
rift valley | 178 |
expression levels | 178 |
neutralizing antibodies | 178 |
blood flow | 178 |
antibiotic therapy | 176 |
income countries | 176 |
cell responses | 176 |
valley fever | 175 |
coronary artery | 175 |
may occur | 175 |
cord injury | 174 |
consecutive patients | 174 |
also found | 174 |
respiratory infection | 174 |
fatty acid | 173 |
abdominal pain | 173 |
computed tomography | 172 |
higher levels | 172 |
binding protein | 172 |
results suggest | 172 |
kidney disease | 171 |
cell entry | 171 |
severe asthma | 171 |
statistical significance | 170 |
liver disease | 170 |
icu stay | 169 |
one study | 169 |
previously described | 168 |
primary outcome | 168 |
nile virus | 168 |
vaccine development | 167 |
recent studies | 167 |
new coronavirus | 167 |
blood products | 167 |
literature review | 166 |
cord blood | 166 |
nitric oxide | 165 |
hong kong | 164 |
previously reported | 164 |
immune cell | 164 |
three patients | 164 |
generation sequencing | 164 |
sofa score | 164 |
risk assessment | 164 |
kg day | 164 |
lopinavir ritonavir | 164 |
metabolic syndrome | 163 |
human coronavirus | 163 |
data analysis | 163 |
may cause | 163 |
pilot study | 163 |
day mortality | 163 |
clinical studies | 162 |
increased susceptibility | 162 |
also known | 162 |
ex vivo | 162 |
mass index | 162 |
several studies | 161 |
significantly reduced | 161 |
body mass | 161 |
cell culture | 160 |
recent years | 160 |
fever virus | 160 |
cytokine production | 160 |
plant mirnas | 160 |
myocardial infarction | 160 |
large number | 159 |
analyzed using | 159 |
human health | 159 |
predictive value | 158 |
type ii | 158 |
may help | 158 |
four patients | 158 |
data suggest | 158 |
mononuclear cells | 158 |
independently associated | 158 |
acute kidney | 158 |
even though | 157 |
neonatal sepsis | 157 |
case fatality | 157 |
supportive care | 156 |
acquired pneumonia | 156 |
inflammatory markers | 156 |
widely used | 156 |
high mortality | 156 |
national health | 156 |
per year | 155 |
red cell | 155 |
multiple sclerosis | 155 |
angiotensin system | 154 |
lymph nodes | 154 |
significantly different | 153 |
mycobacterium tuberculosis | 153 |
lung tissue | 153 |
cell carcinoma | 153 |
confidence interval | 152 |
protein expression | 152 |
average age | 152 |
first year | 151 |
proinflammatory cytokines | 151 |
pandemic influenza | 151 |
dipeptidyl peptidase | 151 |
critical illness | 151 |
study aimed | 150 |
south africa | 150 |
another study | 150 |
dependent manner | 150 |
machine learning | 149 |
virus disease | 149 |
trained immunity | 148 |
cancer cells | 148 |
descriptive study | 148 |
patients may | 148 |
one case | 148 |
care workers | 147 |
nlrp inflammasome | 147 |
older age | 147 |
assessed using | 146 |
randomized clinical | 146 |
cell type | 146 |
gvhd prophylaxis | 146 |
controlled trials | 146 |
antiviral drugs | 146 |
cell activation | 146 |
exome sequencing | 145 |
acute phase | 145 |
high prevalence | 145 |
surfactant protein | 145 |
graft failure | 145 |
gut microbiome | 145 |
fungal infections | 144 |
transcription factors | 144 |
kidney transplant | 144 |
antimicrobial resistance | 143 |
ct scan | 143 |
may contribute | 142 |
supplementary table | 142 |
pulmonary function | 142 |
brain barrier | 142 |
new york | 142 |
antiretroviral therapy | 142 |
specific amplification | 141 |
aged years | 141 |
blood loss | 141 |
significant increase | 141 |
inflammasome activation | 141 |
smooth muscle | 141 |
social distancing | 141 |
rhesus macaques | 140 |
molecular mechanisms | 140 |
airway epithelial | 139 |
age years | 139 |
higher mortality | 139 |
signaling pathway | 138 |
regression model | 137 |
single center | 137 |
associated pneumonia | 137 |
cigarette smoke | 137 |
elderly patients | 137 |
hospital admission | 136 |
significant reduction | 136 |
skeletal muscle | 136 |
clinical outcome | 136 |
two different | 136 |
primary immunodeficiency | 136 |
copd patients | 136 |
heparan sulfate | 135 |
cumulative incidence | 135 |
analysis showed | 135 |
high level | 135 |
sectional study | 135 |
respiratory diseases | 134 |
vertical transmission | 133 |
animal model | 133 |
respiratory illness | 133 |
old male | 133 |
may result | 133 |
chronic inflammation | 133 |
medical center | 133 |
study conducted | 132 |
cancer treatment | 132 |
gastrointestinal tract | 132 |
inflammatory cytokine | 132 |
angiotensin converting | 132 |
chest ct | 132 |
report text | 132 |
gold standard | 132 |
abstract case | 132 |
drug repurposing | 132 |
time pcr | 132 |
immunocompromised patients | 132 |
tissue damage | 131 |
pseudomonas aeruginosa | 131 |
clinically significant | 131 |
univariate analysis | 131 |
airway inflammation | 131 |
platelet count | 131 |
control study | 131 |
also showed | 131 |
per day | 131 |
blood components | 131 |
rna polymerase | 130 |
gut microbiota | 130 |
within hours | 130 |
lymph node | 130 |
streptococcus pneumoniae | 129 |
binding domain | 129 |
cancer survivors | 129 |
diabetic patients | 129 |
human transmission | 128 |
climate change | 128 |
five patients | 128 |
blood bank | 128 |
chronic diseases | 128 |
atrial fibrillation | 128 |
copies ml | 128 |
infection prevention | 128 |
patients developed | 127 |
well tolerated | 127 |
mg day | 127 |
medical care | 126 |
host immune | 126 |
receptor binding | 126 |
cell function | 126 |
year old | 126 |
days post | 126 |
year period | 125 |
infected pneumonia | 125 |
genetic testing | 125 |
plasma membrane | 125 |
organ dysfunction | 125 |
inflammatory mediators | 125 |
protective effect | 125 |
health services | 124 |
closely related | 124 |
results showed | 124 |
rv infection | 124 |
reactive oxygen | 124 |
virus entry | 124 |
inflammatory responses | 124 |
target cells | 124 |
renal replacement | 123 |
current study | 123 |
redox stress | 123 |
hemorrhagic fever | 123 |
clinically relevant | 122 |
better understand | 122 |
study design | 122 |
time points | 122 |
protein kinase | 122 |
lupus erythematosus | 122 |
antibody responses | 122 |
medical staff | 121 |
dna methylation | 121 |
serum levels | 121 |
reverse transcriptase | 121 |
left ventricular | 121 |
clinical signs | 121 |
early diagnosis | 121 |
early stage | 121 |
cmv reactivation | 121 |
protease inhibitor | 121 |
cell count | 120 |
different types | 120 |
cell transplant | 120 |
saharan africa | 120 |
severe respiratory | 120 |
systemic lupus | 120 |
ischemic stroke | 120 |
human lung | 119 |
inflammatory bowel | 119 |
much higher | 119 |
white blood | 119 |
artery disease | 119 |
united kingdom | 119 |
poor prognosis | 119 |
available data | 118 |
study group | 118 |
alveolar macrophages | 118 |
poor outcome | 118 |
confirmed covid | 118 |
chronic kidney | 118 |
sex differences | 118 |
infected individuals | 118 |
independent risk | 118 |
cell receptor | 118 |
multiple organ | 118 |
human cytomegalovirus | 117 |
differential diagnosis | 117 |
viral diseases | 117 |
wang et | 117 |
related mortality | 117 |
specific antibodies | 117 |
allogeneic stem | 117 |
respiratory system | 117 |
months post | 116 |
older patients | 116 |
chronic hepatitis | 116 |
primary endpoint | 116 |
physical exercise | 116 |
myeloid leukemia | 116 |
uk biobank | 116 |
blood culture | 116 |
sleep quality | 116 |
genetic variants | 116 |
first case | 116 |
patients showed | 116 |
also observed | 116 |
resonance imaging | 115 |
positive patients | 115 |
signaling pathways | 115 |
antibody response | 115 |
increased mortality | 115 |
ml min | 115 |
first days | 115 |
children aged | 114 |
analysis revealed | 114 |
convalescent plasma | 114 |
disease burden | 113 |
heart rate | 113 |
treatment options | 113 |
coronavirus infections | 113 |
oxygen species | 113 |
patients hospitalized | 113 |
room temperature | 113 |
low levels | 113 |
retrospective review | 113 |
two cases | 113 |
positive results | 113 |
highly pathogenic | 112 |
severe influenza | 112 |
emerging infectious | 112 |
plasma levels | 112 |
standard deviation | 112 |
high dose | 112 |
prospective cohort | 112 |
million people | 112 |
mechanically ventilated | 112 |
th cells | 112 |
chinese medicine | 112 |
linear regression | 112 |
asthma exacerbations | 111 |
environmental factors | 111 |
immune reconstitution | 111 |
patients presented | 111 |
study included | 111 |
invasive mechanical | 111 |
phase ii | 111 |
may increase | 111 |
body temperature | 111 |
future studies | 111 |
chart review | 111 |
bronchoalveolar lavage | 110 |
primary care | 110 |
allogeneic hsct | 110 |
immune dysregulation | 110 |
significantly decreased | 109 |
disease caused | 109 |
among children | 109 |
national institute | 109 |
north america | 109 |
blood donor | 109 |
close contact | 109 |
next generation | 109 |
medical history | 109 |
adaptive immunity | 109 |
case reports | 109 |
findings suggest | 109 |
also reported | 108 |
respiratory muscle | 108 |
quality control | 108 |
human immune | 108 |
endoplasmic reticulum | 108 |
two weeks | 108 |
small number | 108 |
idiopathic pulmonary | 108 |
immune deficiency | 108 |
oral administration | 107 |
positive cells | 107 |
cell rna | 107 |
patients presenting | 107 |
specific igg | 107 |
patients died | 107 |
old female | 107 |
may provide | 107 |
insulin sensitivity | 107 |
less likely | 107 |
exogenous ncrnas | 107 |
cell response | 107 |
viral genome | 106 |
hospital discharge | 106 |
combination therapy | 106 |
respiratory viral | 106 |
memory cd | 106 |
colorectal cancer | 106 |
adverse reactions | 106 |
social media | 105 |
common cold | 105 |
bowel disease | 105 |
stranded rna | 105 |
dilated cardiomyopathy | 105 |
normal range | 105 |
clinical management | 105 |
cell subsets | 105 |
chen et | 105 |
test results | 104 |
crucial role | 104 |
patients aged | 104 |
differentially expressed | 104 |
hbv infection | 104 |
complete remission | 104 |
leading cause | 104 |
oral mucositis | 104 |
cardiac surgery | 104 |
sialic acid | 104 |
healthy donors | 104 |
risk patients | 103 |
cd cell | 103 |
clinical findings | 103 |
significant association | 103 |
patients diagnosed | 103 |
symptom onset | 103 |
breast milk | 103 |
traditional chinese | 103 |
median duration | 103 |
viral loads | 103 |
male patients | 103 |
like receptors | 103 |
cmv infection | 103 |
soft tissue | 103 |
control measures | 103 |
health professionals | 103 |
decision making | 102 |
blood mononuclear | 102 |
infection may | 102 |
inflammatory diseases | 102 |
last years | 102 |
human cells | 102 |
may play | 102 |
cell membrane | 102 |
epidemiological characteristics | 102 |
baseline characteristics | 101 |
family history | 101 |
cell cycle | 101 |
deficient mice | 101 |
healthy individuals | 101 |
life expectancy | 101 |
previous study | 101 |
cerebrospinal fluid | 101 |
tertiary care | 101 |
significant improvement | 101 |
committee approval | 101 |
potential therapeutic | 100 |
natural history | 100 |
six patients | 100 |
patient care | 100 |
cell lymphoma | 100 |
nucleic acids | 100 |
chest pain | 100 |
cell counts | 100 |
taken together | 100 |
antibiotic treatment | 100 |
membrane oxygenation | 100 |
graft versus | 100 |
bladder cancer | 99 |
broad spectrum | 99 |
blood glucose | 99 |
genetic diversity | 99 |
ncov infection | 99 |
viral pneumonia | 99 |
drug discovery | 99 |
health outcomes | 99 |
common cause | 99 |
social isolation | 99 |
image quality | 99 |
vitro studies | 99 |
higher rates | 99 |
human disease | 99 |
surveillance system | 99 |
observational studies | 98 |
host defense | 98 |
survival rate | 98 |
key role | 98 |
increased levels | 98 |
autoimmune disease | 98 |
additional file | 98 |
global burden | 97 |
results indicate | 97 |
calculated using | 97 |
iu ml | 97 |
severe patients | 97 |
antibiotic use | 97 |
retrospectively reviewed | 97 |
small sample | 97 |
healthy subjects | 97 |
ascorbic acid | 97 |
meningococcal disease | 97 |
low risk | 97 |
host response | 96 |
better understanding | 96 |
epithelial cell | 96 |
diabetic rats | 96 |
study aims | 96 |
ml kg | 96 |
patients requiring | 96 |
measured using | 96 |
first line | 96 |
will also | 96 |
high expression | 95 |
adverse outcomes | 95 |
highly expressed | 95 |
versus host | 95 |
neutrophil extracellular | 95 |
spectrum antiviral | 95 |
solid organ | 95 |
antibiotic prophylaxis | 95 |
squamous cell | 95 |
kidney transplantation | 95 |
mass spectrometry | 95 |
studies suggest | 95 |
coronavirus spike | 95 |
cell lung | 95 |
sore throat | 94 |
drug administration | 94 |
lung diseases | 94 |
prospective observational | 94 |
induced lung | 94 |
effective treatment | 94 |
flow rate | 94 |
blood supply | 94 |
genes involved | 94 |
recurrent infections | 94 |
negative bacteria | 94 |
critical role | 94 |
biliary atresia | 94 |
review board | 94 |
respiratory rate | 94 |
cardiovascular diseases | 93 |
influenza surveillance | 93 |
south korea | 93 |
many countries | 93 |
central venous | 93 |
evidence suggests | 93 |
pneumococcal disease | 93 |
plasmodium falciparum | 93 |
extracellular matrix | 93 |
transfusion reactions | 93 |
intravenous immunoglobulin | 93 |
combined immunodeficiency | 93 |
immune activation | 93 |
human monoclonal | 93 |
newly diagnosed | 92 |
chronic disease | 92 |
median number | 92 |
oxygen saturation | 92 |
sanger sequencing | 92 |
severe pneumonia | 92 |
resistance genes | 92 |
endemic areas | 92 |
encephalitis virus | 92 |
radical prostatectomy | 92 |
blood cultures | 92 |
chronic respiratory | 92 |
early stages | 92 |
naturally occurring | 92 |
transmission dynamics | 91 |
human cd | 91 |
respiratory pathogens | 91 |
patient characteristics | 91 |
female patients | 91 |
human infection | 91 |
traumatic brain | 91 |
rhinovirus infection | 91 |
collected data | 91 |
infectious complications | 91 |
male sex | 91 |
extracorporeal membrane | 91 |
gi tract | 90 |
causative agent | 90 |
false positive | 90 |
whole exome | 90 |
membrane fusion | 90 |
human respiratory | 90 |
nan doi | 90 |
three groups | 90 |
health system | 90 |
binding lectin | 90 |
single cell | 90 |
cardiovascular risk | 90 |
cytokine release | 90 |
inhibitory activity | 90 |
obese patients | 90 |
cells expressing | 89 |
healthy volunteers | 89 |
acute myeloid | 89 |
eight patients | 89 |
high incidence | 89 |
like illness | 89 |
success rate | 89 |
vascular endothelial | 89 |
one month | 89 |
receptor blockers | 89 |
tumor cells | 89 |
studies showed | 89 |
collaborative cross | 89 |
see table | 89 |
south america | 89 |
two years | 89 |
three months | 89 |
severe illness | 89 |
inhibitory effect | 89 |
increased expression | 89 |
patient population | 88 |
myeloid cells | 88 |
described previously | 88 |
determined using | 88 |
retrospectively analyzed | 88 |
resistance mutations | 88 |
barr virus | 88 |
three different | 88 |
blood stem | 88 |
higher incidence | 88 |
diagnostic criteria | 88 |
food intake | 88 |
medicinal plants | 88 |
cigarette smoking | 88 |
inflammatory disease | 88 |
also called | 88 |
infection among | 88 |
ace receptor | 88 |
future research | 88 |
unrelated donor | 88 |
viral particles | 88 |
autoinflammatory diseases | 88 |
care providers | 88 |
three times | 88 |
medical record | 88 |
donor chimerism | 88 |
years ago | 87 |
live attenuated | 87 |
endothelial dysfunction | 87 |
lung inflammation | 87 |
serum creatinine | 87 |
high morbidity | 87 |
small cell | 87 |
antiviral therapy | 87 |
patients included | 87 |
candida albicans | 87 |
phase iii | 87 |
electronic medical | 87 |
study found | 87 |
abo blood | 87 |
interstitial lung | 87 |
hematopoietic cell | 87 |
smoking status | 87 |
institutional review | 86 |
coronary heart | 86 |
severe sepsis | 86 |
sexually transmitted | 86 |
ace activity | 86 |
therapeutic efficacy | 86 |
rhesus macaque | 86 |
extracellular traps | 86 |
com scientificreports | 86 |
fc receptor | 86 |
mrna expression | 86 |
acute asthma | 86 |
poorly understood | 86 |
health commission | 86 |
serum amyloid | 86 |
sex ratio | 86 |
suspected cases | 86 |
operative time | 85 |
gene transcription | 85 |
th percentile | 85 |
demographic characteristics | 85 |
respiratory virus | 85 |
remains unclear | 85 |
many patients | 85 |
vaccine candidates | 85 |
randomized trial | 85 |
health systems | 85 |
tb patients | 85 |
marrow transplantation | 85 |
laboratory findings | 85 |
invasive ventilation | 85 |
human tissues | 85 |
significant decrease | 85 |
potential role | 84 |
also associated | 84 |
currently available | 84 |
human rights | 84 |
epidemiological studies | 84 |
reported cases | 84 |
reverse transcription | 84 |
disease activity | 84 |
mediterranean fever | 84 |
tyrosine kinase | 84 |
essential oils | 84 |
wide association | 84 |
lower levels | 84 |
pattern recognition | 84 |
figure shows | 84 |
working group | 83 |
may affect | 83 |
infectious agents | 83 |
strongly associated | 83 |
disease status | 83 |
competing interests | 83 |
mortality among | 83 |
human population | 83 |
binding site | 83 |
septic patients | 83 |
icu mortality | 83 |
renal disease | 83 |
significant impact | 83 |
prognostic factors | 83 |
regression models | 83 |
protein levels | 83 |
study also | 83 |
exclusion criteria | 83 |
elevated levels | 83 |
lung adenocarcinoma | 83 |
well known | 83 |
rna virus | 83 |
wild type | 82 |
small intestine | 82 |
blood type | 82 |
ace protein | 82 |
klebsiella pneumoniae | 82 |
protease inhibitors | 82 |
ace gene | 82 |
single nucleotide | 82 |
progenitor cells | 82 |
genome sequencing | 82 |
ang ii | 82 |
beneficial effects | 82 |
viral proteins | 82 |
spike glycoprotein | 82 |
data collected | 82 |
ventilated patients | 82 |
seven patients | 82 |
treated patients | 82 |
studies reported | 82 |
systemic inflammatory | 82 |
data analyzed | 82 |
toxoplasma gondii | 82 |
protective equipment | 82 |
early onset | 82 |
oral cavity | 82 |
may reduce | 82 |
macrophage activation | 82 |
ace levels | 81 |
following infection | 81 |
study population | 81 |
poor outcomes | 81 |
disease outbreaks | 81 |
western blot | 81 |
center study | 81 |
influenza pandemic | 81 |
social support | 81 |
done using | 81 |
vero cells | 81 |
patients suffering | 81 |
myeloablative conditioning | 81 |
first step | 81 |
young adults | 81 |
liver transplantation | 81 |
pulmonary embolism | 81 |
hiv prevalence | 81 |
european countries | 81 |
humoral immune | 81 |
incidence rate | 80 |
diagnostic accuracy | 80 |
inflammatory cells | 80 |
plasma cells | 80 |
creative commons | 80 |
functional receptor | 80 |
fold higher | 80 |
patient developed | 80 |
binding affinity | 80 |
nine patients | 80 |
animal health | 80 |
limited data | 80 |
health problem | 80 |
categorical variables | 80 |
grade iii | 80 |
personal protective | 80 |
risk group | 80 |
genes associated | 80 |
murine model | 80 |
endothelial cell | 80 |
rna sequencing | 80 |
data regarding | 79 |
infected mice | 79 |
graft survival | 79 |
opportunistic infections | 79 |
study participants | 79 |
genes encoding | 79 |
virus particles | 79 |
arterial pressure | 79 |
hiv aids | 79 |
icu discharge | 79 |
similar results | 79 |
chronic lung | 79 |
pulmonary tuberculosis | 79 |
complement activation | 79 |
growth factors | 79 |
neutralizing antibody | 79 |
autosomal recessive | 79 |
interquartile range | 79 |
per patient | 79 |
older people | 78 |
ct scans | 78 |
humanized mice | 78 |
antiviral effect | 78 |
associated infections | 78 |
higher rate | 78 |
cancer therapy | 78 |
cells via | 78 |
lymphocyte count | 78 |
treatment option | 78 |
term outcomes | 78 |
efsa supporting | 78 |
knockout mice | 78 |
first hours | 78 |
specific ige | 78 |
pulmonary hypertension | 78 |
antiviral activities | 78 |
antimicrobial peptides | 78 |
previous reports | 78 |
autologous stem | 78 |
supporting publication | 78 |
dependent rna | 77 |
immune complexes | 77 |
china clinical | 77 |
diagnostic tests | 77 |
group compared | 77 |
receptor ace | 77 |
exogenous rnas | 77 |
class ii | 77 |
oxygen therapy | 77 |
host factors | 77 |
studies using | 77 |
patient outcomes | 77 |
therapeutic options | 77 |
real time | 77 |
correlation coefficient | 77 |
advanced cancer | 77 |
also shown | 77 |
human infections | 77 |
patient safety | 77 |
national institutes | 77 |
blood vessels | 77 |
psychological distress | 77 |
also demonstrated | 76 |
twice daily | 76 |
acute leukemia | 76 |
institutional affiliations | 76 |
rna synthesis | 76 |
vast majority | 76 |
litter size | 76 |
written informed | 76 |
relatively high | 76 |
survival rates | 76 |
human body | 76 |
healthcare professionals | 76 |
familial mediterranean | 76 |
renal transplant | 76 |
body fluids | 76 |
direct contact | 76 |
springer nature | 76 |
published maps | 76 |
overall mortality | 75 |
specific antibody | 75 |
nosocomial infections | 75 |
human papillomavirus | 75 |
organ transplantation | 75 |
preliminary results | 75 |
may represent | 75 |
alcohol consumption | 75 |
health workers | 75 |
cd ra | 75 |
surgical site | 75 |
killer cells | 75 |
nature remains | 75 |
neurocritical care | 75 |
showed significant | 75 |
human metapneumovirus | 75 |
remains neutral | 75 |
factor receptor | 75 |
lymphocyte subsets | 75 |
tidal volume | 75 |
extracellular vesicles | 75 |
significant correlation | 75 |
eucalyptus camaldulensis | 75 |
fmf patients | 75 |
developed countries | 75 |
fungal infection | 75 |
mainland china | 75 |
jurisdictional claims | 75 |
cause mortality | 74 |
time point | 74 |
also used | 74 |
protective effects | 74 |
commercially available | 74 |
chemokine receptor | 74 |
arterial hypertension | 74 |
pediatric population | 74 |
patients reported | 74 |
healthcare facilities | 74 |
patients required | 74 |
bacterial pathogens | 74 |
life cycles | 74 |
study using | 74 |
dihydrofolate reductase | 74 |
igg levels | 74 |
plasma samples | 74 |
chemical constituents | 74 |
analysis using | 74 |
publicly available | 74 |
lassa fever | 73 |
drinking water | 73 |
lpv rtv | 73 |
antiviral agents | 73 |
enzyme activity | 73 |
current smokers | 73 |
mhc class | 73 |
matched unrelated | 73 |
will help | 73 |
potential risk | 73 |
clinical research | 73 |
physical examination | 73 |
among others | 73 |
autosomal dominant | 73 |
positive correlation | 73 |
reproduction number | 73 |
dendritic cell | 73 |
measles virus | 73 |
grade ii | 73 |
tested positive | 73 |
bronchial epithelial | 73 |
drug development | 73 |
antiviral drug | 73 |
cases reported | 72 |
significantly improved | 72 |
ejection fraction | 72 |
recombinant human | 72 |
acute exacerbations | 72 |
clinical information | 72 |
fold increase | 72 |
structural proteins | 72 |
randomized trials | 72 |
continuous variables | 72 |
laboratory tests | 72 |
clinical significance | 72 |
red cells | 72 |
gay men | 72 |
demographic data | 72 |
animal studies | 72 |
human airway | 72 |
baloxavir marboxil | 72 |
liver failure | 72 |
genetic variation | 72 |
clinical study | 72 |
compared using | 72 |
genetic analysis | 72 |
platelet concentrates | 72 |
mice infected | 72 |
acute renal | 72 |
patients compared | 72 |
inflammatory effects | 72 |
safety profile | 72 |
major cause | 71 |
binding sites | 71 |
scoring system | 71 |
risk groups | 71 |
zhang et | 71 |
literature search | 71 |
treatment failure | 71 |
killer cell | 71 |
general hospital | 71 |
retrospective chart | 71 |
among different | 71 |
autoinflammatory disease | 71 |
negative patients | 71 |
west africa | 71 |
thermo fisher | 71 |
clinical samples | 71 |
african american | 71 |
therapeutic target | 71 |
recent advances | 71 |
genomic dna | 71 |
hazard ratio | 71 |
cancer cell | 71 |
early detection | 71 |
surveillance data | 71 |
well established | 71 |
cell migration | 70 |
viral respiratory | 70 |
secondary bacterial | 70 |
ace inhibitors | 70 |
antiviral treatment | 70 |
month period | 70 |
new insights | 70 |
liver transplant | 70 |
one third | 70 |
six months | 70 |
likely due | 70 |
case study | 70 |
first study | 70 |
disease prevention | 70 |
imaging findings | 70 |
significant risk | 70 |
cell development | 70 |
primary human | 70 |
based study | 70 |
sars patients | 69 |
response rate | 69 |
identified using | 69 |
lower risk | 69 |
infection rate | 69 |
health problems | 69 |
bacterial pneumonia | 69 |
guangdong province | 69 |
resistant bacteria | 69 |
containing protein | 69 |
viral pathogens | 69 |
smoking history | 69 |
health authorities | 69 |
clinical use | 69 |
bl mice | 69 |
dry cough | 69 |
relatively low | 69 |
disease course | 69 |
complete response | 69 |
lg pd | 69 |
none declared | 69 |
conditioning regimens | 69 |
cytomegalovirus infection | 69 |
gene therapy | 69 |
transmitted infections | 69 |
may serve | 69 |
medical conditions | 69 |
high frequency | 69 |
adverse event | 68 |
antimicrobial therapy | 68 |
health emergency | 68 |
chikungunya virus | 68 |
major role | 68 |
new cases | 68 |
li et | 68 |
density lipoprotein | 68 |
phylogenetic analysis | 68 |
raw milk | 68 |
cell source | 68 |
will need | 68 |
less severe | 68 |
cell differentiation | 68 |
supplementary figure | 68 |
conducted using | 68 |
communicable diseases | 68 |
dromedary camels | 68 |
dependent enhancement | 68 |
adhesion molecule | 68 |
secondary outcomes | 68 |
health status | 68 |
higher prevalence | 68 |
viral clearance | 68 |
abstract withdrawn | 68 |
age range | 68 |
borne diseases | 68 |
elderly people | 68 |
clinical diagnosis | 68 |
will provide | 67 |
clinical improvement | 67 |
remains unknown | 67 |
high rate | 67 |
apache ii | 67 |
common symptoms | 67 |
positive cases | 67 |
urinary incontinence | 67 |
transgenic mice | 67 |
serine protease | 67 |
chronic inflammatory | 67 |
whole genome | 67 |
cardiac output | 67 |
key words | 67 |
connective tissue | 67 |
prognostic value | 67 |
tumor growth | 67 |
many studies | 67 |
dengue fever | 67 |
arterial blood | 67 |
study shows | 67 |
total rna | 67 |
chinese center | 67 |
disease risk | 67 |
disease transmission | 67 |
side effect | 67 |
lymphoblastic leukemia | 67 |
tb infection | 67 |
pulmonary edema | 67 |
data available | 66 |
cerebral edema | 66 |
times higher | 66 |
fatality rates | 66 |
ros production | 66 |
wide variety | 66 |
study reported | 66 |
first reported | 66 |
may improve | 66 |
randomised controlled | 66 |
yang et | 66 |
subarachnoid hemorrhage | 66 |
will require | 66 |
viral shedding | 66 |
transplant patients | 66 |
expression level | 66 |
light chain | 66 |
social contact | 66 |
included studies | 66 |
higher proportion | 66 |
adhesion molecules | 66 |
critical cases | 66 |
multivariate logistic | 66 |
nutritional status | 66 |
also significantly | 66 |
high doses | 66 |
may require | 66 |
nonhuman primates | 66 |
statistical analyses | 66 |
influenza vaccines | 66 |
cell populations | 66 |
two studies | 66 |
patient age | 66 |
hodgkin lymphoma | 65 |
results obtained | 65 |
rank test | 65 |
greater risk | 65 |
cancer care | 65 |
mers coronavirus | 65 |
copy number | 65 |
cohort studies | 65 |
vivo studies | 65 |
th day | 65 |
north carolina | 65 |
receiver operating | 65 |
study clinical | 65 |
acute lymphoblastic | 65 |
identify patients | 65 |
missing data | 65 |
radiation therapy | 65 |
underlying disease | 65 |
low dose | 65 |
intervention group | 65 |
ige levels | 65 |
viral dna | 64 |
prospective studies | 64 |
wuhan city | 64 |
relative risk | 64 |
identified patients | 64 |
may develop | 64 |
otitis media | 64 |
glucose metabolism | 64 |
lung epithelial | 64 |
essential oil | 64 |
risk stratification | 64 |
depressive symptoms | 64 |
care medicine | 64 |
year os | 64 |
retrospective observational | 64 |
infections among | 64 |
considered statistically | 64 |
protective role | 64 |
within months | 64 |
immunosuppressive therapy | 64 |
supplementary fig | 64 |
functional outcome | 64 |
different countries | 64 |
smoke exposure | 64 |
human cases | 64 |
blood donations | 64 |
pcr assay | 64 |
quantitative pcr | 64 |
juvenile idiopathic | 64 |
lonicera japonica | 64 |
carbon dioxide | 64 |
patients experienced | 64 |
healthcare providers | 64 |
sickle cell | 64 |
early childhood | 64 |
mammalian cells | 64 |
telomere length | 64 |
cell survival | 64 |
antimicrobial susceptibility | 64 |
patient died | 64 |
susceptibility testing | 63 |
cell adhesion | 63 |
among adults | 63 |
antiviral effects | 63 |
might also | 63 |
epidemiological data | 63 |
nipah virus | 63 |
de la | 63 |
declare background | 63 |
relapse mortality | 63 |
idiopathic arthritis | 63 |
humanized mouse | 63 |
controlled study | 63 |
underlying diseases | 63 |
clinical isolates | 63 |
alveolar epithelial | 63 |
may explain | 63 |
also identified | 63 |
falciparum malaria | 63 |
gestational age | 63 |
treatment strategies | 63 |
pao fio | 63 |
cfu ml | 63 |
giant cell | 63 |
mycophenolate mofetil | 63 |
rabies virus | 63 |
early phase | 63 |
drug resistant | 63 |
anxiety symptoms | 63 |
successfully treated | 63 |
bat origin | 62 |
infection risk | 62 |
human coronaviruses | 62 |
urgent need | 62 |
japanese encephalitis | 62 |
trend towards | 62 |
urban areas | 62 |
outcomes among | 62 |
angiotensin receptor | 62 |
corona virus | 62 |
term survival | 62 |
sheep milk | 62 |
european society | 62 |
molecular weight | 62 |
transfusion medicine | 62 |
urgently needed | 62 |
primary infection | 62 |
confidence intervals | 62 |
roc curve | 62 |
vsmc proliferation | 62 |
lupus patients | 62 |
unrelated donors | 62 |
therapeutic targets | 61 |
cardiac injury | 61 |
line treatment | 61 |
infections may | 61 |
randomly assigned | 61 |
table shows | 61 |
limited number | 61 |
bglu activity | 61 |
reduced intensity | 61 |
multicenter study | 61 |
antigen presentation | 61 |
candidate genes | 61 |
genomic rna | 61 |
cell depletion | 61 |
serum samples | 61 |
health insurance | 61 |
long time | 61 |
emergency room | 61 |
primary immune | 61 |
cardiovascular events | 61 |
drug delivery | 61 |
studies conducted | 61 |
corticosteroid therapy | 61 |
cx cr | 61 |
wound healing | 61 |
prolonged exercise | 61 |
person transmission | 60 |
information regarding | 60 |
research support | 60 |
cell therapy | 60 |
high rates | 60 |
immune functions | 60 |
old man | 60 |
samples collected | 60 |
severe infections | 60 |
socioeconomic status | 60 |
high sensitivity | 60 |
lipid peroxidation | 60 |
high affinity | 60 |
smooth myocytes | 60 |
longitudinal study | 60 |
pulmonary arterial | 60 |
mechanisms underlying | 60 |
liver function | 60 |
also present | 60 |
southeast asia | 60 |
preliminary data | 60 |
infected animals | 60 |
neuraminidase inhibitors | 60 |
intensity conditioning | 60 |
negative results | 60 |
rat model | 60 |
related genes | 60 |
blood groups | 60 |
receptor antagonist | 60 |
sepsis patients | 60 |
donor selection | 60 |
cell growth | 60 |
elevated serum | 60 |
one hundred | 60 |
acquired infections | 60 |
weight gain | 59 |
pid patients | 59 |
hydrogen peroxide | 59 |
cd expression | 59 |
highly conserved | 59 |
highest risk | 59 |
stimulating factor | 59 |
solid tumors | 59 |
data set | 59 |
preventive measures | 59 |
genetic factors | 59 |
health conditions | 59 |
sex hormones | 59 |
presenting cells | 59 |
formyl peptide | 59 |
target genes | 59 |
organ transplant | 59 |
gastrointestinal symptoms | 59 |
positively correlated | 59 |
small molecule | 59 |
descriptive statistics | 59 |
acute exacerbation | 59 |
disease onset | 59 |
single dose | 59 |
infection rates | 59 |
results show | 59 |
human cell | 59 |
early life | 59 |
partial response | 59 |
people living | 59 |
studies show | 59 |
blood product | 59 |
related diseases | 59 |
type iii | 59 |
related complications | 59 |
cell wall | 59 |
peptide receptor | 59 |
may influence | 58 |
including patients | 58 |
note springer | 58 |
negative predictive | 58 |
antiviral response | 58 |
blood gas | 58 |
status epilepticus | 58 |
evaluated using | 58 |
complement system | 58 |
broad range | 58 |
least two | 58 |
important factor | 58 |
cox regression | 58 |
healthcare system | 58 |
multivariable logistic | 58 |
major histocompatibility | 58 |
associated protein | 58 |
high fever | 58 |
post infection | 58 |
clinical picture | 58 |
ovarian cancer | 58 |
mean arterial | 58 |
line therapy | 58 |
severe clinical | 58 |
contact tracing | 58 |
organ donation | 58 |
teaching hospital | 58 |
day post | 58 |
care system | 58 |
cells ul | 58 |
square test | 58 |
lassa virus | 58 |
resistance training | 58 |
secondary infections | 58 |
hematological malignancies | 58 |
systematic reviews | 58 |
significantly less | 58 |
african americans | 58 |
enzyme inhibitors | 58 |
dna polymerase | 57 |
first years | 57 |
fluid resuscitation | 57 |
extended data | 57 |
two decades | 57 |
secondary infection | 57 |
one hand | 57 |
muscle cells | 57 |
und die | 57 |
asian countries | 57 |
time period | 57 |
renal dysfunction | 57 |
higher number | 57 |
term outcome | 57 |
systemic corticosteroids | 57 |
molecular patterns | 57 |
severe combined | 57 |
cell disease | 57 |
preschool children | 57 |
gene encoding | 57 |
functional outcomes | 57 |
oral mucosa | 57 |
task force | 57 |
viral envelope | 57 |
deep learning | 57 |
human rhinovirus | 57 |
tmprss expression | 57 |
exact test | 57 |
progressive multifocal | 57 |
ns delrluc | 57 |
current knowledge | 57 |
clinical relevance | 57 |
vaccine design | 57 |
cells may | 57 |
minimally invasive | 57 |
irf ko | 57 |
quality improvement | 57 |
binding proteins | 57 |
plant ncrnas | 56 |
remaining patients | 56 |
matched sibling | 56 |
ferritin levels | 56 |
protein synthesis | 56 |
supplementary material | 56 |
first report | 56 |
illness severity | 56 |
expression data | 56 |
pneumonia outbreak | 56 |
acute care | 56 |
study demonstrated | 56 |
human influenza | 56 |
first day | 56 |
last decade | 56 |
infections caused | 56 |
human ace | 56 |
cell receptors | 56 |
nuclear factor | 56 |
broadly neutralizing | 56 |
health service | 56 |
observational cohort | 56 |
sensitivity analysis | 56 |
tuberculosis infection | 56 |
aldosterone system | 56 |
prostate biopsy | 56 |
virus transmission | 56 |
using spss | 56 |
periodic fever | 56 |
rhesus monkeys | 56 |
recognition receptors | 56 |
intracranial pressure | 56 |
granulomatous disease | 56 |
function mutations | 56 |
sequencing data | 56 |
health law | 56 |
acute graft | 56 |
also included | 56 |
financial interests | 56 |
serum albumin | 56 |
disease resistance | 56 |
viral titers | 55 |
aa amyloidosis | 55 |
care hospital | 55 |
pulmonary inflammation | 55 |
rbv rifn | 55 |
group received | 55 |
white matter | 55 |
study suggests | 55 |
positive predictive | 55 |
crp levels | 55 |
entry depends | 55 |
particulate matter | 55 |
year follow | 55 |
cd count | 55 |
less common | 55 |
former smokers | 55 |
people aged | 55 |
significant effect | 55 |
common variable | 55 |
zikv rna | 55 |
human primates | 55 |
laboratory testing | 55 |
organ damage | 55 |
prion infection | 55 |
huang et | 55 |
related acute | 55 |
ten patients | 55 |
multivariable analysis | 55 |
affected patients | 55 |
lymphoid tissue | 55 |
neck cancer | 55 |
mild symptoms | 55 |
clinical care | 55 |
signal transduction | 55 |
molecular biology | 55 |
skin rash | 55 |
ciliated cells | 55 |
histocompatibility complex | 55 |
will likely | 55 |
may present | 55 |
data fig | 55 |
derived macrophages | 55 |
patient received | 55 |
high number | 55 |
clinical response | 55 |
antimicrobial activity | 55 |
way anova | 55 |
neutrophil engraftment | 55 |
mediated immune | 54 |
detection rate | 54 |
intermediate host | 54 |
hospital admissions | 54 |
skin lesions | 54 |
cellular uptake | 54 |
less frequently | 54 |
swine fever | 54 |
human plasma | 54 |
bile acids | 54 |
first months | 54 |
glass opacities | 54 |
older children | 54 |
trauma patients | 54 |
cancer diagnosis | 54 |
phage display | 54 |
severe ards | 54 |
mortality risk | 54 |
transforming growth | 54 |
coronavirus outbreak | 54 |
mediated immunity | 54 |
international congresses | 54 |
mean duration | 54 |
may include | 54 |
serious adverse | 54 |
acid residues | 54 |
available evidence | 54 |
heavy chain | 54 |
predictive factors | 54 |
viral protein | 54 |
linked immunosorbent | 54 |
hsct recipients | 54 |
lesser extent | 54 |
tb disease | 54 |
inflammatory conditions | 54 |
neurological symptoms | 54 |
cell population | 54 |
primary immunodeficiencies | 54 |
time course | 54 |
smoking cessation | 54 |
treated mice | 54 |
multidisciplinary team | 54 |
insulin secretion | 54 |
respiratory specimens | 54 |
secretory cells | 54 |
vaccinia virus | 54 |
previously published | 54 |
one week | 54 |
urinary retention | 54 |
term follow | 54 |
open access | 54 |
lung pathology | 54 |
zhao et | 54 |
antiviral immunity | 54 |
results may | 54 |
clinical presentations | 53 |
induced acute | 53 |
ubiquitin ligase | 53 |
cc strains | 53 |
rna replication | 53 |
urethral stricture | 53 |
targeted therapy | 53 |
phylogenetic trees | 53 |
cruciate ligament | 53 |
humoral immunity | 53 |
several factors | 53 |
uric acid | 53 |
also contribute | 53 |
beneficial effect | 53 |
global public | 53 |
current status | 53 |
possible role | 53 |
small rnas | 53 |
association study | 53 |
multifocal leukoencephalopathy | 53 |
molecular basis | 53 |
blood volume | 53 |
liquid chromatography | 53 |
iron deficiency | 53 |
blood transfusions | 53 |
hiv transmission | 53 |
glycemic control | 53 |
deceased patients | 53 |
unclear whether | 53 |
shock patients | 53 |
frequently used | 53 |
promising results | 53 |
rna shedding | 53 |
hepatocellular carcinoma | 53 |
global pandemic | 53 |
envelope protein | 53 |
mm patients | 53 |
antibody screening | 53 |
often associated | 53 |
old age | 53 |
primary objective | 53 |
imaging features | 53 |
gene mutations | 53 |
cytokine levels | 53 |
third trimester | 53 |
hematologic malignancies | 53 |
umbilical cord | 53 |
past years | 53 |
provide evidence | 53 |
partial nephrectomy | 53 |
antibody production | 53 |
viral disease | 53 |
immune suppression | 53 |
vaccine efficacy | 53 |
brain death | 53 |
comorbid conditions | 53 |
two independent | 52 |
disease among | 52 |
worse outcomes | 52 |
mixed chimerism | 52 |
younger patients | 52 |
protease activity | 52 |
associated molecular | 52 |
rna expression | 52 |
hiv patients | 52 |
pivotal role | 52 |
every year | 52 |
zoonotic diseases | 52 |
south african | 52 |
asthma exacerbation | 52 |
polluted weather | 52 |
high concentrations | 52 |
cognitive impairment | 52 |
early identification | 52 |
expression profiles | 52 |
large cohort | 52 |
factors including | 52 |
drug use | 52 |
myocardial injury | 52 |
relatively small | 52 |
disease patients | 52 |
radiation dose | 52 |
receptor expression | 52 |
vascular smooth | 52 |
enveloped viruses | 52 |
active site | 52 |
invasive fungal | 52 |
factors affecting | 52 |
preterm infants | 52 |
human populations | 52 |
glasgow coma | 52 |
also occur | 51 |
radical cystectomy | 51 |
information system | 51 |
release syndrome | 51 |
latin america | 51 |
outbreak associated | 51 |
membrane protein | 51 |
patients will | 51 |
increasing number | 51 |
published data | 51 |
operating characteristic | 51 |
vaccination program | 51 |
slightly higher | 51 |
mycobacterium avium | 51 |
adult inpatients | 51 |
circulating levels | 51 |
old girl | 51 |
current evidence | 51 |
rural areas | 51 |
surgical treatment | 51 |
lactate dehydrogenase | 51 |
immunosuppressive drugs | 51 |
regulatory factor | 51 |
birth weight | 51 |
cell numbers | 51 |
tissue distribution | 51 |
york city | 51 |
ebov gp | 51 |
increased incidence | 51 |
exercise training | 51 |
ct imaging | 51 |
marrow transplant | 51 |
cov spike | 51 |
analysed using | 51 |
empiric antibiotic | 51 |
results demonstrate | 51 |
see figure | 51 |
patients using | 51 |
different age | 51 |
expression profiling | 51 |
incidence rates | 51 |
mg twice | 51 |
underlying mechanisms | 51 |
inhibitory effects | 51 |
diseases including | 51 |
airway epithelium | 51 |
chronic graft | 51 |
nucleotide polymorphisms | 51 |
year post | 51 |
cardiovascular mortality | 51 |
assess whether | 51 |
showed significantly | 51 |
ct images | 51 |
cause severe | 50 |
many cases | 50 |
compound heterozygous | 50 |
five years | 50 |
clinical development | 50 |
still unclear | 50 |
kim et | 50 |
infected children | 50 |
healthy adults | 50 |
united nations | 50 |
central role | 50 |
immunosorbent assay | 50 |
mouth disease | 50 |
clinical setting | 50 |
total population | 50 |
pet ct | 50 |
variable immunodeficiency | 50 |
salivary glands | 50 |
last follow | 50 |
chemically modified | 50 |
interim guidance | 50 |
two main | 50 |
febrile illness | 50 |
intravascular coagulation | 50 |
experimental rhinovirus | 50 |
glomerular filtration | 50 |
therapeutic strategies | 50 |
factors influencing | 50 |
acute viral | 50 |
blood services | 50 |
erectile function | 50 |
neurological outcome | 50 |
sample sizes | 50 |
study protocol | 50 |
three cases | 50 |
wu et | 50 |
health concern | 50 |
study will | 50 |
collected specimens | 50 |
among people | 50 |
mortality due | 50 |
human igg | 50 |
liu et | 50 |
laboratory parameters | 50 |
generated using | 50 |
pleural effusion | 50 |
recently published | 50 |
transmembrane protein | 50 |
medical treatment | 50 |
radiological findings | 50 |
transmission potential | 50 |
tissue culture | 50 |
severe symptoms | 50 |
three years | 50 |
listeria monocytogenes | 49 |
human herpesvirus | 49 |
electron microscopy | 49 |
cases per | 49 |
probable bat | 49 |
clinical severity | 49 |
significant morbidity | 49 |
glucose uptake | 49 |
like symptoms | 49 |
also important | 49 |
antimicrobial peptide | 49 |
clinical disease | 49 |
rheumatic diseases | 49 |
enzymatic activity | 49 |
highly effective | 49 |
first two | 49 |
related changes | 49 |
dna damage | 49 |
platelet engraftment | 49 |
among older | 49 |
mg daily | 49 |
reperfusion injury | 49 |
african swine | 49 |
diagnostic performance | 49 |
female sex | 49 |
outcome measures | 49 |
prospectively collected | 49 |
ace mrna | 49 |
genetic susceptibility | 49 |
american college | 49 |
takes place | 49 |
severe complications | 49 |
acute severe | 49 |
tobacco smoke | 49 |
related symptoms | 49 |
infect humans | 49 |
therapeutic effect | 49 |
gender differences | 49 |
standard treatment | 49 |
residual disease | 49 |
supporting information | 49 |
invasive pneumococcal | 49 |
specific cd | 49 |
antibiotic susceptibility | 49 |
disease outcomes | 49 |
prognostic factor | 49 |
infectious virus | 49 |
wastewater treatment | 49 |
acute myocardial | 49 |
failure assessment | 49 |
mesenchymal stem | 49 |
clinical implications | 49 |
one day | 48 |
reduced risk | 48 |
inhaled corticosteroids | 48 |
human blood | 48 |
protective immunity | 48 |
goblet cells | 48 |
positive test | 48 |
biological effects | 48 |
additional information | 48 |
cells mm | 48 |
progressive disease | 48 |
clinical status | 48 |
clinical parameters | 48 |
best practices | 48 |
cd receptors | 48 |
average number | 48 |
drug interactions | 48 |
first identified | 48 |
multiorgan failure | 48 |
fc receptors | 48 |
eculizumab recipients | 48 |
flow cytometric | 48 |
additional studies | 48 |
chronic infection | 48 |
one hour | 48 |
lung damage | 48 |
endemic countries | 48 |
ms ms | 48 |
human leukocyte | 48 |
febrile neutropenia | 48 |
hcv infection | 48 |
haploidentical donor | 48 |
whitney test | 48 |
higher expression | 48 |
comparative study | 48 |
study including | 48 |
blood sample | 48 |
novel human | 48 |
improve patient | 48 |
resistant strains | 48 |
old boy | 48 |
therapeutic approaches | 48 |
biological processes | 48 |
dengue hemorrhagic | 48 |
blood banks | 48 |
stimulated genes | 48 |
based approach | 48 |
antibacterial activity | 48 |
care professionals | 48 |
many different | 48 |
viral hepatitis | 48 |
years post | 48 |
data indicate | 48 |
muscle mass | 48 |
treated cells | 48 |
myocardial ischemia | 48 |
interferon response | 48 |
genetic background | 48 |
haemophilus influenzae | 48 |
bloodstream infections | 47 |
disease pathogenesis | 47 |
hiv incidence | 47 |
experimental models | 47 |
mtb rif | 47 |
sibling donor | 47 |
data showed | 47 |
time series | 47 |
zoonotic disease | 47 |
patient reported | 47 |
associated periodic | 47 |
recently reported | 47 |
major risk | 47 |
large proportion | 47 |
human pathogens | 47 |
fully human | 47 |
disseminated intravascular | 47 |
increased significantly | 47 |
chronic granulomatous | 47 |
cat unc | 47 |
serum ferritin | 47 |
year survival | 47 |
disease surveillance | 47 |
laboratory data | 47 |
human serum | 47 |
younger age | 47 |
inflammatory activity | 47 |
adult population | 47 |
health benefits | 47 |
imsr cat | 47 |
cells kg | 47 |
rsv infection | 47 |
acid substitutions | 47 |
renal cell | 47 |
following criteria | 47 |
patients achieved | 47 |
lc gabarap | 47 |
health effects | 47 |
antigen expression | 47 |
nontuberculous mycobacterial | 47 |
ulcerative colitis | 47 |
platelet counts | 47 |
activated protein | 47 |
carolina imsr | 47 |
obese individuals | 47 |
posted march | 47 |
least days | 47 |
experimental group | 47 |
data obtained | 47 |
standard therapy | 47 |
enrolled patients | 47 |
general anesthesia | 47 |
icu length | 47 |
surface area | 47 |
fisher scientific | 47 |
strong evidence | 47 |
liver injury | 47 |
cells within | 47 |
male mice | 47 |
main cause | 47 |
patients whose | 47 |
stress response | 47 |
associated coronavirus | 47 |
antimicrobial stewardship | 47 |
human host | 47 |
highly sensitive | 46 |
receptor signaling | 46 |
immunoglobulin replacement | 46 |
matched related | 46 |
endothelial growth | 46 |
treatment group | 46 |
high resolution | 46 |
proven protease | 46 |
disease may | 46 |
new therapeutic | 46 |
pneumocystis jirovecii | 46 |
high degree | 46 |
low level | 46 |
free radicals | 46 |
iav infection | 46 |
corticosteroid treatment | 46 |
may act | 46 |
zinc supplementation | 46 |
also performed | 46 |
neisseria gonorrhoeae | 46 |
targeted therapies | 46 |
death rate | 46 |
kidney function | 46 |
proinflammatory cytokine | 46 |
died due | 46 |
mouse strains | 46 |
first cases | 46 |
stromal cells | 46 |
crystal structure | 46 |
air pollutants | 46 |
lymphoid tissues | 46 |
cellular immune | 46 |
lavage fluid | 46 |
positive samples | 46 |
isothermal amplification | 46 |
electronic health | 46 |
bariatric surgery | 46 |
ii receptor | 46 |
care services | 46 |
much lower | 46 |
emerging viruses | 46 |
patient survival | 46 |
pneumonia associated | 46 |
adverse effect | 46 |
exogenous plant | 46 |
wide spectrum | 46 |
mean follow | 46 |
may become | 46 |
ace tmprss | 46 |
total score | 46 |
fat diet | 46 |
brain mri | 46 |
clinical evaluation | 46 |
pathogenic avian | 46 |
cervical cancer | 46 |
therapeutic agents | 46 |
investigate whether | 46 |
clinical suspicion | 46 |
antibody titers | 46 |
common among | 46 |
inhibitory concentration | 46 |
treatment outcomes | 46 |
human antibody | 45 |
graft function | 45 |
erectile dysfunction | 45 |
health literacy | 45 |
recurrent fever | 45 |
affinity maturation | 45 |
chagas disease | 45 |
two major | 45 |
platelet activation | 45 |
cardiac death | 45 |
studies revealed | 45 |
considered significant | 45 |
blood collection | 45 |
global warming | 45 |
emergency nurses | 45 |
drug therapy | 45 |
clinically proven | 45 |
xpert mtb | 45 |
oral care | 45 |
antigen receptor | 45 |
many years | 45 |
effectively inhibit | 45 |
thoracic society | 45 |
seafood market | 45 |
sustainable development | 45 |
clinical phenotype | 45 |
three days | 45 |
donor age | 45 |
chest radiographs | 45 |
european union | 45 |
different stages | 45 |
tissue samples | 45 |
intracerebral hemorrhage | 45 |
plasma concentrations | 45 |
health laws | 45 |
amniotic fluid | 45 |
showed higher | 45 |
online survey | 45 |
national blood | 45 |
early transmission | 45 |
mean time | 45 |
red wine | 45 |
practice guidelines | 45 |
asymptomatic patients | 45 |
equine encephalitis | 45 |
important lessons | 45 |
also increased | 45 |
vital signs | 45 |
kj mol | 45 |
underlying conditions | 45 |
mean number | 45 |
gene polymorphism | 45 |
years later | 45 |
gene polymorphisms | 45 |
per cell | 45 |
net formation | 45 |
air quality | 45 |
two days | 45 |
obese mice | 45 |
ii score | 45 |
useful tool | 45 |
patients years | 45 |
month follow | 45 |
kinase inhibitor | 45 |
severe malaria | 45 |
ethical approval | 45 |
text introduction | 45 |
pediatric cases | 45 |
publication bias | 45 |
positive result | 45 |
igg antibodies | 45 |
airway obstruction | 45 |
marrow failure | 45 |
pneumonia caused | 44 |
therapeutic potential | 44 |
immune checkpoint | 44 |
cd binding | 44 |
average time | 44 |
pulmonary tb | 44 |
sequential organ | 44 |
died within | 44 |
national level | 44 |
every weeks | 44 |
platelet transfusion | 44 |
different levels | 44 |
negative impact | 44 |
rbc transfusion | 44 |
negatively correlated | 44 |
east asia | 44 |
one patients | 44 |
cell membranes | 44 |
may benefit | 44 |
across different | 44 |
disease outbreak | 44 |
digestive tract | 44 |
hospital length | 44 |
scientificreports www | 44 |
renal transplantation | 44 |
pediatric intensive | 44 |
cell viability | 44 |
normal lung | 44 |
sulfate proteoglycans | 44 |
past decade | 44 |
successful treatment | 44 |
patients transplanted | 44 |
genetic basis | 44 |
care facilities | 44 |
internal medicine | 44 |
infections due | 44 |
human diseases | 44 |
requiring mechanical | 44 |
multiplex pcr | 44 |
biological fluids | 44 |
performance status | 44 |
pneumococcal conjugate | 44 |
mainly due | 44 |
zoster virus | 44 |
obese subjects | 44 |
coronavirus associated | 44 |
respiratory epithelial | 44 |
capsid protein | 44 |
high quality | 44 |
rna genome | 44 |
treatment regimens | 44 |
among women | 44 |
chimeric antigen | 44 |
different populations | 44 |
cytokine responses | 44 |
investigated whether | 44 |
highly active | 44 |
hemolytic anemia | 44 |
physical function | 44 |
immunosuppressed patients | 44 |
plasma exchange | 44 |
childhood asthma | 44 |
streptococcus agalactiae | 44 |
salivary gland | 44 |